{"hands_on_practices": [{"introduction": "Effective antibiotic therapy, especially with narrow therapeutic index drugs like aminoglycosides, relies on tailoring doses to the individual. This first practice exercise [@problem_id:4578369] walks you through a core task in therapeutic drug monitoring: calculating a patient's specific elimination half-life ($t_{1/2}$) and systemic clearance ($CL$) from post-dose serum concentrations. Understanding this process is fundamental to interpreting clinical data and personalizing treatment.", "problem": "A $70\\,\\mathrm{kg}$ adult with stable renal function receives an intravenous gentamicin dose over $0.5\\,\\mathrm{h}$. Post-distribution serum concentrations (assay validated; sampling timed from the end of infusion) are measured at $t_1 = 2.0\\,\\mathrm{h}$ with $C_1 = 6.80\\,\\mathrm{mg/L}$ and at $t_2 = 6.5\\,\\mathrm{h}$ with $C_2 = 1.45\\,\\mathrm{mg/L}$. Assume a one-compartment model with first-order elimination once distribution is complete and monoexponential decline over the sampling interval. A prior individualized pharmacokinetic assessment has established an apparent volume of distribution $V_d = 19.6\\,\\mathrm{L}$ for this patient.\n\nUsing only the two measured post-distribution concentrations and times, and the stated modeling assumptions, determine the elimination half-life $t_{1/2}$ and the systemic clearance $CL$ for gentamicin in this patient under the one-compartment, first-order framework. Round each reported quantity to three significant figures. Express $t_{1/2}$ in hours and $CL$ in $\\mathrm{L/h}$. Provide your final answer as a row vector $\\big[t_{1/2},\\,CL\\big]$.", "solution": "The problem is first subjected to validation.\n\n### Step 1: Extract Givens\n- Patient mass: $70\\,\\mathrm{kg}$\n- Patient condition: adult with stable renal function\n- Drug administration: intravenous dose over $0.5\\,\\mathrm{h}$\n- Modeling assumption: one-compartment model with first-order elimination, monoexponential decline post-distribution\n- Sampling time origin: end of infusion\n- First data point: concentration $C_1 = 6.80\\,\\mathrm{mg/L}$ at time $t_1 = 2.0\\,\\mathrm{h}$\n- Second data point: concentration $C_2 = 1.45\\,\\mathrm{mg/L}$ at time $t_2 = 6.5\\,\\mathrm{h}$\n- Apparent volume of distribution: $V_d = 19.6\\,\\mathrm{L}$\n- Required outputs: elimination half-life $t_{1/2}$ (in hours) and systemic clearance $CL$ (in $\\mathrm{L/h}$)\n- Required precision: round to three significant figures\n- Final answer format: row vector $\\big[t_{1/2},\\,CL\\big]$\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, employing the standard one-compartment first-order elimination model, which is a fundamental and appropriate approximation for the pharmacokinetics of aminoglycosides like gentamicin in the post-distribution phase. The provided data, including serum concentrations and the volume of distribution ($V_d \\approx 0.28\\,\\mathrm{L/kg}$, which is typical for gentamicin), are within clinically plausible ranges. The problem is well-posed; it provides two concentration-time points, which are sufficient to determine the elimination rate constant, and the volume of distribution, which is necessary to calculate clearance. The problem statement is objective, precise, and internally consistent. It is a standard pharmacokinetic calculation problem.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will be derived.\n\nThe solution proceeds by first determining the elimination rate constant ($k_e$) from the two provided serum concentration-time points. Subsequently, the elimination half-life ($t_{1/2}$) and systemic clearance ($CL$) are calculated from $k_e$ and the given volume of distribution ($V_d$).\n\nUnder a one-compartment model with first-order elimination, the drug concentration $C(t)$ in the post-distribution, post-infusion phase declines monoexponentially according to the equation:\n$$ C(t) = C(0) \\exp(-k_e t) $$\nwhere $C(0)$ is the hypothetical concentration at the end of the infusion (time $t=0$), and $k_e$ is the first-order elimination rate constant.\n\nGiven two concentration measurements, $C_1$ at time $t_1$ and $C_2$ at time $t_2$, we can write:\n$$C_1 = C(0) \\exp(-k_e t_1)$$\n$$C_2 = C(0) \\exp(-k_e t_2)$$\n\nTo find $k_e$, we can take the ratio of $C_2$ to $C_1$:\n$$ \\frac{C_2}{C_1} = \\frac{C(0) \\exp(-k_e t_2)}{C(0) \\exp(-k_e t_1)} = \\exp(-k_e(t_2 - t_1)) $$\nTaking the natural logarithm of both sides gives:\n$$ \\ln\\left(\\frac{C_2}{C_1}\\right) = -k_e (t_2 - t_1) $$\nSolving for $k_e$:\n$$ k_e = -\\frac{\\ln(C_2/C_1)}{t_2 - t_1} = \\frac{\\ln(C_1/C_2)}{t_2 - t_1} $$\nSubstituting the given values: $C_1 = 6.80\\,\\mathrm{mg/L}$, $t_1 = 2.0\\,\\mathrm{h}$, $C_2 = 1.45\\,\\mathrm{mg/L}$, and $t_2 = 6.5\\,\\mathrm{h}$.\n$$ k_e = \\frac{\\ln\\left(\\frac{6.80}{1.45}\\right)}{6.5 - 2.0} = \\frac{\\ln(4.689655...)}{4.5\\,\\mathrm{h}} $$\n$$ k_e \\approx \\frac{1.54536}{4.5\\,\\mathrm{h}} \\approx 0.343414\\,\\mathrm{h^{-1}} $$\n\nThe elimination half-life, $t_{1/2}$, is the time required for the drug concentration to decrease by half. It is related to $k_e$ by the formula:\n$$ t_{1/2} = \\frac{\\ln(2)}{k_e} $$\nSubstituting the calculated value for $k_e$:\n$$ t_{1/2} = \\frac{\\ln(2)}{0.343414\\,\\mathrm{h^{-1}}} \\approx \\frac{0.693147}{0.343414\\,\\mathrm{h^{-1}}} \\approx 2.0184\\,\\mathrm{h} $$\nRounding to three significant figures, the elimination half-life is $t_{1/2} = 2.02\\,\\mathrm{h}$.\n\nSystemic clearance, $CL$, is defined as the volume of plasma cleared of the drug per unit time. In a one-compartment model, it is the product of the apparent volume of distribution, $V_d$, and the elimination rate constant, $k_e$:\n$$ CL = k_e \\cdot V_d $$\nUsing the given value $V_d = 19.6\\,\\mathrm{L}$ and the calculated $k_e$:\n$$ CL = (0.343414\\,\\mathrm{h^{-1}}) \\times (19.6\\,\\mathrm{L}) \\approx 6.73091\\,\\mathrm{L/h} $$\nRounding to three significant figures, the systemic clearance is $CL = 6.73\\,\\mathrm{L/h}$.\n\nThe requested quantities are the elimination half-life, $t_{1/2} = 2.02\\,\\mathrm{h}$, and the systemic clearance, $CL = 6.73\\,\\mathrm{L/h}$. These are to be presented as a row vector.", "answer": "$$\\boxed{\\begin{pmatrix} 2.02 & 6.73 \\end{pmatrix}}$$", "id": "4578369"}, {"introduction": "After determining a patient's clearance, the next step is designing a rational dosing regimen. This exercise [@problem_id:4578325] challenges you to develop an extended-interval aminoglycoside dosing plan *a priori*, using an estimate of renal function to calculate the minimum dosing interval ($\\tau$) needed to keep trough levels below a toxicity threshold. This practice bridges the gap between patient assessment and regimen design, a critical skill for minimizing aminoglycoside-associated nephrotoxicity.", "problem": "A $68$-year-old female with measured body weight $W = 52$ kg and serum creatinine $SCr = 1.4$ mg/dL is to receive an intravenous aminoglycoside with concentration-dependent bactericidal activity. Assume linear pharmacokinetics, a one-compartment body model, and first-order elimination. The aminoglycoside is administered as instantaneous intravenous bolus doses every $\\tau$ hours, with bioavailability $F = 1$, negligible plasma protein binding, and renal elimination approximated by glomerular filtration. The target is to maintain the steady-state trough concentration immediately before the next dose less than $1$ mg/L to minimize nephrotoxicity while permitting high peaks.\n\nUse the Cockcroft–Gault creatinine clearance formula, including the sex-specific multiplier for females,\n$$CrCl = \\frac{(140 - \\text{age}) \\times W}{72 \\times SCr} \\times 0.85$$\nto estimate renal function. Model the drug’s total clearance as equal to creatinine clearance converted to liters per hour. Use a volume of distribution $V_d = 0.25$ L/kg and an initial dose $D = 5$ mg/kg.\n\nStarting from first principles of one-compartment first-order elimination and the superposition principle for multiple dosing, determine the minimal dosing interval $\\tau$ (in hours) such that the steady-state trough concentration equals $1$ mg/L. Intervals longer than this will maintain the trough below $1$ mg/L. Express the final dosing interval in hours and round your answer to three significant figures. Use mg/L for concentrations and hours for time units throughout.", "solution": "The problem is valid as it is scientifically grounded in established principles of clinical pharmacokinetics, is self-contained, well-posed, objective, and provides realistic clinical data for a formalizable calculation.\n\nThe objective is to determine the minimal dosing interval $\\tau$ for an intravenous aminoglycoside administered as a bolus dose, such that the steady-state trough concentration, $C_{ss,min}$, is exactly $1$ mg/L. A longer interval would result in a trough concentration below this target.\n\nThe analysis is based on a one-compartment body model with first-order elimination. For a single instantaneous intravenous bolus dose $D$, the plasma concentration $C(t)$ at time $t$ is given by:\n$$C(t) = C_0 \\exp(-k_e t)$$\nwhere $C_0 = \\frac{D}{V_d}$ is the initial concentration at $t=0$, $V_d$ is the volume of distribution, and $k_e$ is the first-order elimination rate constant.\n\nFor a multiple dosing regimen with a constant dose $D$ administered every $\\tau$ hours, the superposition principle leads to the concentration at steady state. The trough concentration at steady state, $C_{ss,min}$, which occurs immediately before the next dose, is given by the sum of the residual concentrations from all previous doses. This can be expressed as:\n$$C_{ss,min} = C_{ss,max} \\exp(-k_e \\tau)$$\nwhere $C_{ss,max}$ is the peak concentration at steady state. The peak concentration is given by:\n$$C_{ss,max} = \\frac{D/V_d}{1 - \\exp(-k_e \\tau)}$$\nSubstituting the expression for $C_{ss,max}$ into the equation for $C_{ss,min}$ yields:\n$$C_{ss,min} = \\left( \\frac{D/V_d}{1 - \\exp(-k_e \\tau)} \\right) \\exp(-k_e \\tau) = \\frac{D}{V_d} \\frac{\\exp(-k_e \\tau)}{1 - \\exp(-k_e \\tau)}$$\nWe must solve this equation for the dosing interval $\\tau$. Let's rearrange the terms:\n$$C_{ss,min} \\left( 1 - \\exp(-k_e \\tau) \\right) = \\frac{D}{V_d} \\exp(-k_e \\tau)$$\n$$C_{ss,min} = C_{ss,min} \\exp(-k_e \\tau) + \\frac{D}{V_d} \\exp(-k_e \\tau)$$\n$$C_{ss,min} = \\exp(-k_e \\tau) \\left( C_{ss,min} + \\frac{D}{V_d} \\right)$$\n$$\\exp(-k_e \\tau) = \\frac{C_{ss,min}}{C_{ss,min} + D/V_d} = \\frac{C_{ss,min} V_d}{C_{ss,min} V_d + D}$$\nTaking the natural logarithm of both sides:\n$$-k_e \\tau = \\ln\\left( \\frac{C_{ss,min} V_d}{C_{ss,min} V_d + D} \\right)$$\n$$\\tau = -\\frac{1}{k_e} \\ln\\left( \\frac{C_{ss,min} V_d}{C_{ss,min} V_d + D} \\right) = \\frac{1}{k_e} \\ln\\left( \\left(\\frac{C_{ss,min} V_d}{C_{ss,min} V_d + D}\\right)^{-1} \\right)$$\n$$\\tau = \\frac{1}{k_e} \\ln\\left( \\frac{C_{ss,min} V_d + D}{C_{ss,min} V_d} \\right) = \\frac{1}{k_e} \\ln\\left( 1 + \\frac{D}{C_{ss,min} V_d} \\right)$$\nTo use this formula, we must first calculate the patient's specific pharmacokinetic parameters: total clearance ($CL$), volume of distribution ($V_d$), and elimination rate constant ($k_e$).\n\nFirst, we calculate the creatinine clearance ($CrCl$) using the provided Cockcroft–Gault formula for a female patient.\nGiven data: age = $68$ years, weight $W = 52$ kg, serum creatinine $SCr = 1.4$ mg/dL.\n$$CrCl = \\frac{(140 - \\text{age}) \\times W}{72 \\times SCr} \\times 0.85$$\n$$CrCl = \\frac{(140 - 68) \\times 52}{72 \\times 1.4} \\times 0.85 = \\frac{72 \\times 52}{100.8} \\times 0.85 = \\frac{3744}{100.8} \\times 0.85 \\approx 37.14286 \\times 0.85 \\approx 31.5714 \\text{ mL/min}$$\n\nNext, we convert $CrCl$ to total clearance $CL$ in units of L/h.\n$$CL = 31.5714 \\frac{\\text{mL}}{\\text{min}} \\times \\frac{1 \\text{ L}}{1000 \\text{ mL}} \\times \\frac{60 \\text{ min}}{1 \\text{ h}} = 1.89428 \\text{ L/h}$$\n\nNow, we calculate the volume of distribution $V_d$ and the dose $D$.\nGiven $V_d$ per kg $= 0.25$ L/kg and $W = 52$ kg:\n$$V_d = 0.25 \\frac{\\text{L}}{\\text{kg}} \\times 52 \\text{ kg} = 13 \\text{ L}$$\nGiven dose per kg $= 5$ mg/kg and $W = 52$ kg:\n$$D = 5 \\frac{\\text{mg}}{\\text{kg}} \\times 52 \\text{ kg} = 260 \\text{ mg}$$\n\nWith $CL$ and $V_d$, we can find the elimination rate constant $k_e$.\n$$k_e = \\frac{CL}{V_d} = \\frac{1.89428 \\text{ L/h}}{13 \\text{ L}} \\approx 0.145714 \\text{ h}^{-1}$$\n\nFinally, we substitute all calculated values into the derived equation for $\\tau$.\nGiven target $C_{ss,min} = 1$ mg/L.\n$$\\tau = \\frac{1}{k_e} \\ln\\left( 1 + \\frac{D}{C_{ss,min} V_d} \\right)$$\n$$\\tau = \\frac{1}{0.145714 \\text{ h}^{-1}} \\ln\\left( 1 + \\frac{260 \\text{ mg}}{(1 \\text{ mg/L})(13 \\text{ L})} \\right)$$\n$$\\tau = \\frac{1}{0.145714} \\ln\\left( 1 + \\frac{260}{13} \\right) = \\frac{1}{0.145714} \\ln(1 + 20)$$\n$$\\tau = \\frac{\\ln(21)}{0.145714} \\approx \\frac{3.044522}{0.145714} \\approx 20.8938 \\text{ hours}$$\n\nRounding the final answer to three significant figures, we get:\n$$\\tau \\approx 20.9 \\text{ hours}$$", "answer": "$$\\boxed{20.9}$$", "id": "4578325"}, {"introduction": "Not all antimicrobials are optimized using the same PK/PD index. This final practice [@problem_id:4578326] shifts our focus to fluoroquinolones, where efficacy is driven by the free drug area under the curve relative to the MIC ($f\\text{AUC}_{24}/\\text{MIC}$). You will apply fundamental pharmacokinetic principles to calculate the daily oral dose required to meet a specific efficacy target, highlighting the versatility of PK/PD concepts across different drug classes.", "problem": "An adult patient with a Gram-negative bacterial infection is to be treated with oral levofloxacin. For fluoroquinolones, the pharmacokinetic/pharmacodynamic (PK/PD) index that best correlates with efficacy against Gram-negative organisms is the ratio of the 24-hour free (unbound) area under the concentration–time curve to the minimum inhibitory concentration, denoted $fAUC_{24}/MIC$. The clinician selects a target $f\\text{AUC}_{24}/\\text{MIC}=125$ based on organism susceptibility and clinical goals. Levofloxacin exhibits linear pharmacokinetics in this patient, its absolute oral bioavailability is $F=0.99$, plasma protein binding is $30\\%$, and the total body clearance is $CL=12$ $\\mathrm{L}/\\mathrm{h}$. The organism’s minimum inhibitory concentration (MIC) is $0.25$ $\\mathrm{mg}/\\mathrm{L}$. Assume once-daily dosing at steady state and that the unbound fraction in plasma equals the fraction available to distribute and be eliminated.\n\nUsing only foundational definitions for clearance, area under the concentration–time curve, and free drug fraction, determine the single daily oral dose (in $\\mathrm{mg}$) that achieves the target $f\\text{AUC}_{24}/\\text{MIC}=125$. Round your answer to four significant figures and express the dose in $\\mathrm{mg}$.", "solution": "The problem requires the calculation of a single daily oral dose of levofloxacin to achieve a predefined pharmacokinetic/pharmacodynamic (PK/PD) target. The solution will be systematically derived using fundamental definitions from clinical pharmacology.\n\nFirst, the validity of the problem is established. All provided data and definitions are standard in the field of pharmacokinetics and are scientifically sound.\n- Target PK/PD index: $\\frac{fAUC_{24}}{MIC} = 125$\n- Absolute oral bioavailability: $F = 0.99$\n- Plasma protein binding: $30\\%$\n- Total body clearance: $CL = 12 \\, \\mathrm{L}/\\mathrm{h}$\n- Minimum inhibitory concentration: $MIC = 0.25 \\, \\mathrm{mg}/\\mathrm{L}$\n- Dosing regimen: once-daily, at steady state. This implies a dosing interval of $\\tau = 24 \\, \\mathrm{h}$.\n\nThe problem is well-posed, with all necessary parameters provided, and the objective is stated clearly. The values are clinically realistic for levofloxacin therapy. The problem is therefore deemed valid and a solution can be derived.\n\nAt steady state, the rate of drug administration is equal to the rate of drug elimination. For an orally administered drug, the average rate of administration over a dosing interval $\\tau$ is $\\frac{F \\times \\text{Dose}}{\\tau}$. The rate of elimination is the product of the total body clearance ($CL$) and the average steady-state plasma concentration ($C_{ss, \\text{avg}}$).\n$$ \\text{Rate of Elimination} = CL \\times C_{ss, \\text{avg}} $$\nThe average steady-state concentration is defined as the area under the concentration-time curve over one dosing interval ($AUC_{\\tau, ss}$) divided by that interval $\\tau$.\n$$ C_{ss, \\text{avg}} = \\frac{AUC_{\\tau, ss}}{\\tau} $$\nBy equating the rate of administration and the rate of elimination, we have:\n$$ \\frac{F \\times \\text{Dose}}{\\tau} = CL \\times \\frac{AUC_{\\tau, ss}}{\\tau} $$\nThis fundamental relationship simplifies to an expression for the total drug area under the curve over one dosing interval:\n$$ AUC_{\\tau, ss} = \\frac{F \\times \\text{Dose}}{CL} $$\nFor this problem, the dosing is once daily, so the dosing interval $\\tau$ is $24 \\, \\mathrm{h}$. The relevant area under the curve is the one over a $24$-hour period at steady state, denoted $AUC_{24}$. The dose in the equation corresponds to the total dose administered in that $24$-hour period, which is the single daily dose we seek.\n$$ AUC_{24} = \\frac{F \\times \\text{Dose}}{CL} $$\nThe specified PK/PD target involves the *free* (unbound) drug concentration. The fraction of drug in plasma that is unbound, $f_u$, is calculated from the given plasma protein binding of $30\\%$, or $0.30$.\n$$ f_u = 1 - (\\text{fraction bound}) = 1 - 0.30 = 0.70 $$\nThe free area under the curve, $fAUC_{24}$, is the product of the free fraction $f_u$ and the total area under the curve $AUC_{24}$.\n$$ fAUC_{24} = f_u \\times AUC_{24} $$\nSubstituting the expression for $AUC_{24}$:\n$$ fAUC_{24} = f_u \\times \\left( \\frac{F \\times \\text{Dose}}{CL} \\right) $$\nThe PK/PD target is given as $\\frac{fAUC_{24}}{MIC} = 125$. To ensure dimensional correctness, we must analyze the units. The units of $AUC$ are concentration $\\times$ time (e.g., $\\mathrm{mg} \\cdot \\mathrm{h}/\\mathrm{L}$), and the units of $MIC$ are concentration (e.g., $\\mathrm{mg}/\\mathrm{L}$). Therefore, the ratio $\\frac{AUC}{MIC}$ has units of time. The target value of $125$ is conventionally understood in this context to represent $125 \\, \\mathrm{h}$. Let's denote this target value as $T = 125 \\, \\mathrm{h}$.\n$$ \\frac{fAUC_{24}}{MIC} = T $$\nWe can now substitute our expression for $fAUC_{24}$ into this target equation:\n$$ \\frac{1}{MIC} \\left( f_u \\times \\frac{F \\times \\text{Dose}}{CL} \\right) = T $$\nTo find the required dose, we solve this equation for $\\text{Dose}$:\n$$ \\text{Dose} = \\frac{T \\times MIC \\times CL}{f_u \\times F} $$\nNow we insert the numerical values into the derived formula:\n- $T = 125 \\, \\mathrm{h}$\n- $MIC = 0.25 \\, \\mathrm{mg}/\\mathrm{L}$\n- $CL = 12 \\, \\mathrm{L}/\\mathrm{h}$\n- $f_u = 0.70$\n- $F = 0.99$\n\n$$ \\text{Dose} = \\frac{125 \\, \\mathrm{h} \\times 0.25 \\, \\mathrm{mg}/\\mathrm{L} \\times 12 \\, \\mathrm{L}/\\mathrm{h}}{0.70 \\times 0.99} $$\nThe units in the numerator cancel to $\\mathrm{mg}$, and the denominator is dimensionless, yielding a dose in $\\mathrm{mg}$ as required.\nLet us compute the value of the numerator:\n$$ 125 \\times 0.25 \\times 12 = 375 $$\nLet us compute the value of the denominator:\n$$ 0.70 \\times 0.99 = 0.693 $$\nFinally, we calculate the dose:\n$$ \\text{Dose} = \\frac{375}{0.693} \\approx 541.125541... \\, \\mathrm{mg} $$\nThe problem requires the answer to be rounded to four significant figures.\n$$ \\text{Dose} \\approx 541.1 \\, \\mathrm{mg} $$\nThus, the single daily oral dose of levofloxacin required to meet the therapeutic target is $541.1 \\, \\mathrm{mg}$.", "answer": "$$\\boxed{541.1}$$", "id": "4578326"}]}